PDCD1 and cancer: Checkpoint inhibitors represent a novel category of cancer treatments that have been utilized over the past ten years, with a focus on blocking the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) pathways.